Clinical Scorecard: Exploring the Use of Endotoxin Activity Assay in Sepsis Management: A Scoping Review
At a Glance
Category
Detail
Condition
Sepsis and endotoxemia
Key Mechanisms
Detection of endotoxin (LPS) activity via neutrophil oxidative burst triggered by immune complexes involving LPS Lipid A, mouse anti-Lipid A IgM antibodies, and complement proteins
Target Population
Critically ill human patients with suspected or confirmed sepsis
Care Setting
Hospital critical care units, intensive care units
Key Highlights
Sepsis causes high global mortality; endotoxin from Gram-negative bacteria is a key factor in septic shock.
Endotoxin Activity Assay (EAA) offers rapid (~30 min), specific detection of endotoxin activity in whole blood, overcoming limitations of traditional LAL assay.
EAA results stratified as low (<0.4), intermediate (0.4–0.59), and high (≥0.60) activity, though clinical interpretation and cut-offs remain controversial.
Guideline-Based Recommendations
Diagnosis
Use EAA for rapid and specific detection of endotoxin activity in suspected sepsis patients.
Consider EAA alongside clinical assessment as EAA and LAL assay results may not correlate.
Recognize elevated EAA levels can occur in patients without overt Gram-negative infection, including viral infections with bacterial translocation.
Management
Identify patients with high EAA levels who may benefit from endotoxin removal therapies such as polymyxin B hemoadsorption.
Use EAA to enrich patient selection in clinical trials targeting endotoxin removal.
Be cautious interpreting extremely high EAA values (>0.9) as they may indicate endotoxin levels beyond effective removal by standard therapies.
Monitoring & Follow-up
Measure EAA levels rapidly (~30 minutes) using whole blood samples to guide timely clinical decisions.
Monitor changes in EAA values to assess endotoxin burden and response to therapy.
Risks
Potential for false interpretation due to lack of established absolute cut-off values and variability in EAA levels across patient populations.
EAA cannot be used in murine models due to mouse IgM antibodies in assay.
High endotoxin levels indicated by EAA may predict poor response to endotoxin adsorption therapies.
Patient & Prescribing Data
Critically ill adult patients with sepsis or septic shock, including those with Gram-negative bacterial infections and viral infections with bacterial translocation.
EAA-guided identification of patients for endotoxin removal therapies may improve precision medicine approaches; ongoing trials (e.g., Tigris trial) are evaluating clinical benefits.
Clinical Best Practices
Incorporate EAA testing early in sepsis management to detect endotoxemia rapidly.
Use EAA results in conjunction with clinical findings and other biomarkers for comprehensive assessment.
Apply manufacturer-recommended EAA stratification cautiously, considering emerging evidence on alternative thresholds.
Recognize limitations of EAA in extremely high endotoxin levels and consider alternative or adjunctive therapies.
Stay updated on ongoing clinical trial results to refine EAA use in precision critical care.
